---
title: Atrasentan in Patients with IgA Nephropathy
date: '2024-10-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39460694/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241027204038&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In this prespecified interim analysis, atrasentan resulted
  in a significant and clinically meaningful reduction in proteinuria as compared
  with placebo in patients with IgA nephropathy. (Funded by Novartis; ALIGN ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: In this prespecified interim analysis, atrasentan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo in patients with IgA nephropathy. (Funded by Novartis; ALIGN ClinicalTrials.gov number, ...